Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study

Ma, Zhiyong; Li, Hongwei; Wang, Bin; Shen, Qibin; Cui, Enhai; Lü, Min; Qian, Fuchu; Ping, Jinliang; Dai, Licheng

doi:10.1007/s00432-012-1357-1

Cited by 8 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shimada et al reported that serum midkine levels were obviously increased in esophageal squamous cell carcinoma patients compared with healthy peoples and correlated with tumor size, immunoreactivity, and poor survival [28]. In lung cancer patients, Ma et al showed that midkine mRNA level in peripheral blood mononuclear cells was significantly increased than that in groups of healthy volunteers and positively correlated with clinical stage, differentiated degree, and lymph node metastasis [16]. Zhu et al found that serum midkine levels were significantly elevated in hepatocellular cancer patients and significantly decreased in hepatocellular cancer patients after curative resection and re-increased when tumor recrudesced [29].…”

Section: Discussionmentioning

confidence: 96%

“…In the past few decades, there was more evidence indicating the overexpression of midkine in tumor tissues or serum of cancer patients, such as oral squamous cell carcinoma [11], gastrointestinal cancer [12], colorectal cancer [13], hepatobiliary carcinoma [14], intrahepatic cholangiocarcinoma [15], lung cancer [16], thyroid papillary carcinoma [17], lymphoblastic leukemia [18], cervical cancer [19], ovarian cancer [20], and prostate cancer [21].…”

Section: Discussionmentioning

confidence: 99%

“…Midkine plays critical roles in tumor development and progression through regulating cell proliferation [6], cell motility [7], cell survival [8], angiogenesis [9], and transformation of fibroblasts [10]. The messenger RNA (mRNA) and protein levels of midkine expression have also been found to be elevated in a variety of human cancers such as oral squamous cell carcinoma [11], gastrointestinal cancer [12], colorectal cancer [13], hepatobiliary carcinoma [14], intrahepatic cholangiocarcinoma [15], lung cancer [16], thyroid papillary carcinoma [17], lymphoblastic leukemia [18], cervical cancer [19], ovarian cancer [20], and prostate cancer [21]. However, the clinical significance of midkine protein expression in breast cancer patients remains unknown.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The clinical and prognostic significance of midkine in breast cancer patients

Tian

Zhang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Midkine overexpression has been shown to be a tumor biomarker in several types of human cancer, but little is known about the clinical significance of midkine in breast cancer patients. The aim of this study was to analyze the expression of midkine in breast cancer and its correlation with clinicopathological characteristics, including breast cancer patient's survival. The expression status of midkine in breast cancer from Gene Expression Omnibus (GEO accession number: GDS3853) was observed initially. Furthermore, the expression of midkine messenger RNA (mRNA) and protein was examined in breast cancer and normal mammary tissues through real-time PCR and immunohistochemistry. Moreover, the relationship of midkine protein expression with clinical characteristics of 170 breast cancer patients was analyzed by immunohistochemistry. In our results, midkine was up-expressed in breast cancer tissues compared with normal mammary tissues in microarray data (GDS3853). Midkine mRNA and protein expression was significantly increased in breast cancer tissues than in normal mammary tissues. By immunohistochemistry, high levels of midkine protein were positively associated with the status of clinical stage, T classification, N classification, and M classification in breast cancer patients. Furthermore, midkine overexpression was an independent poor prognostic indicator for the survival of patients with breast cancer. In conclusion, overexpression of midkine protein serves as an unfavorable prognostic biomarker in breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The clinical and prognostic significance of midkine in breast cancer patients

Tian

Zhang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

show abstract

“…There are a number of downstream effectors of the WT1 genes [13]. For example, the heparin-binding growth factor midkine ( MK ) gene is a prognostic biomarker for various cancers [14], [15]. The insulin-like growth factor I receptor (IGF-I-R) is another known downstream effector [16].…”

Section: Discussionmentioning

confidence: 99%

Overexpression of Wilms Tumor 1 Gene as a Negative Prognostic Indicator in Acute Myeloid Leukemia

Lyu

Xin

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Chromosomal aberrations are useful in assessing treatment options and clinical outcomes of acute myeloid leukemia (AML) patients. However, 40∼50% of the AML patients showed no chromosomal abnormalities, i.e., with normal cytogenetics aka the CN-AML patients. Testing of molecular aberrations such as FLT3 or NPM1 can help to define clinical outcomes in the CN-AML patients but with various successes. Goal of this study was to test the possibility of Wilms’ tumor 1 (WT1) gene overexpression as an additional molecular biomarker. A total of 103 CN-AML patients, among which 28% had overexpressed WT1, were studied over a period of 38 months. Patient’s response to induction chemotherapy as measured by the complete remission (CR) rate, disease-free survival (DFS) and overall survival (OS) were measured. Our data suggested that WT1 overexpression correlated negatively with the CR rate, DFS and OS. Consistent with previous reports, CN-AML patients can be divided into three different risk subgroups based on the status of known molecular abnormalities, i.e., the favorable (NPM1mt/no FLT3ITD), the unfavorable (FLT3ITD) and the intermediate risk subgroups. The WT1 overexpression significantly reduced the CR, DFS and OS in both the favorable and unfavorable groups. As the results, patients with normal WT1 gene expression in the favorable risk group showed the best clinical outcomes and all survived with complete remission and disease-free survival over the 37 month study period; in contrast, patients with WT1 overexpression in the unfavorable risk group displayed the worst clinical outcomes. WT1 overexpression by itself is an independent and negative indicator for predicting CR rate, DFS and OS of the CN-AML patients; moreover, it increases the statistical power of predicting the same clinical outcomes when it is combined with the NPM1 mt or the FLT3 ITD genotypes that are the good or poor prognostic markers of CN-AML.

show abstract

“…Overexpression of MDK has been observed in many cancers, including lung cancer ( Hao et al. , 2013 ; Ma et al. , 2013 ), gastric cancer ( Xu et al.…”

Section: Introductionmentioning

confidence: 99%

Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK)

Luo

Wang

Xia

et al. 2015

MBoC

View full text Add to dashboard Cite

show abstract

Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study

Abstract: MK mRNA level in PBMC may be a potential non-invasive molecular marker for the diagnosis of primary NSCLC.

Cited by 8 publications

References 17 publications

The clinical and prognostic significance of midkine in breast cancer patients

The clinical and prognostic significance of midkine in breast cancer patients

Overexpression of Wilms Tumor 1 Gene as a Negative Prognostic Indicator in Acute Myeloid Leukemia

Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK)

Contact Info

Product

Resources

About